Entinostat (MS-275) [39] and Tacedinaline (CI994) [40] are the first potent selective inhibitors of class I HDACs and have shown therapeutic potential by ameliorating inflammation in preclinical models of various inflammatory and autoimmune diseases, including RA [41], Chronic Obstructive Pulmonary Disease (COPD) [42], pancreatitis (19), inflammation associated with angiotensin II-induced hypertension [43], liver fibrosis [44], and lipopolysaccharide-induced acute kidney injury (LPS-AKI) [45]. This evidence concerns the gene AGT and hypertensive disorder.